Caladrius Biosciences, Inc. (NASDAQ: CLBS) Starts Presentation at 29th Annual ROTH Conference
Caladrius Biosciences (NASDAQ: CLBS) is advancing a proprietary platform technology for immunomodulation by pioneering the use of T regulatory cells as an innovative therapy for recent onset type 1 diabetes. The company’s product candidate, CLBS03, is the subject of an ongoing phase 2 clinical trial in collaboration with Sanford Research, and has been granted Orphan Drug and Fast Track designation by the FDA and Advanced Therapeutic Medicinal Product classification by the European Medicines Agency. The company’s PCT subsidiary is a development and manufacturing partner to the cell therapy industry. For more information, visit the company’s website at www.caladrius.com. About NetworkNewsWire NetworkNewsWire…